Altimmune, Inc.

ALT Healthcare Biotechnology

Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.46 0.10 −3.91%
Market cap
$498.0M
P/E
0.0×
Fwd P/E
−3.9×
Dividend yield
—
F-score
4/9
Altman Z
0.23
Beneish M
−3.17
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
4 2 — — 2 4 3 3 4 2
Altman Z-Score
0.23 12.45 18.25 18.47 9.20 8.32 (2.17) (4.08) (3.25) —
P/S ratio
6,914.26 25,596.73 1,314.92 0.00 85.75 35.33 4.28 0.56 2.41 0.00
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
0.63 (3.94) 8.19 5.76 8.83 14.19 (0.93) (0.16) (5.77) 0.70
Beneish M-Score
(3.17) 6.02 — — (3.77) 1.38 (3.96) (5.99) (0.80) (0.21)
P/Operating CF
(16.35) (28.03) (33.88) (42.38) (17.21) (21.77) (12.39) (1.12) (5.39) 0.00
P/B ratio
1.41 4.15 2.89 3.96 1.90 1.28 0.55 0.12 0.66 0.00
Price to Tangible BV
1.50 4.61 3.08 4.24 2.03 1.36 0.76 0.17 38.48 0.00
EV/Sales
1,717.80 19,023.93 851.59 (8,079.20) 42.88 9.15 (1.86) (2.69) 1.32 (0.81)
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.54 1.58 0.00 0.24
EV/Operating CF
(1.17) (4.76) (4.79) (8.78) (2.42) (2.18) 1.13 2.96 (0.70) 0.41
EV/FCF
(1.17) (4.75) (4.77) (8.73) (2.09) (2.16) 1.12 2.68 (0.70) 0.40
Quick Ratio
18.35 12.90 16.69 10.99 10.73 19.00 9.92 8.58 5.85 0.74
Current Ratio
18.55 13.11 17.26 11.31 11.17 19.16 10.04 8.70 6.11 0.82
Net Debt/EBITDA
2.49 1.24 2.31 2.10 1.96 3.95 1.78 1.92 0.77 0.26
Debt/Assets
12.25% 0.00% 0.00% 0.32% 0.51% 0.60% 2.75% 0.92% 0.00% 0.04%
Debt/Equity
0.15 0.00 0.00 0.00 0.01 0.01 0.03 0.01 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.02 0.05 0.11 0.18 0.21 0.11
Operating CF/Net income
0.77 0.84 0.86 0.74 0.81 0.70 0.46 0.22 0.39 0.55
Capex/Depreciation
0.01 0.00 0.00 0.61 (22.34) (0.80) (0.07) (0.04) 0.00 (1.63)
Interest Coverage
(57.76) (11,463.56) (2,740.83) (10,967.50) (19,382.80) (5,829.65) (9,302.23) (144.17) (321.07) (288.10)
ROE
(50.57%) (59.86%) (46.63%) (44.07%) (45.69%) (36.14%) (44.70%) (96.86%) (143.46%) (46.90%)
ROA
(42.03%) (54.33%) (42.36%) (39.79%) (41.85%) (32.79%) (38.55%) (72.13%) (101.26%) (39.32%)
ROIC
0.00% 0.00% 0.00% (5,217.65%) (610.37%) (300.78%) (131.45%) (185.13%) (120.07%) (23.62%)
Return on Tangible Assets
(33.43%) (74.73%) (44.64%) (47.90%) (51.84%) (22.36%) (57.34%) (117.39%) (253.87%) 1,421.79%
Average Days of Receivables
15,463.54 56,885.25 4,158.09 (13,639.19) 483.27 551.76 103.83 157.96 345.61 134.28
Research and Development Expense of Revenue
162,029.27% 411,130.00% 15,445.77% (103,732.35%) 1,690.27% 608.12% 306.23% 178.68% 171.41% 223.15%
Selling, General and Administrative Expense of Revenue
68,531.71% 104,830.00% 4,257.51% (25,197.06%) 349.50% 161.39% 146.53% 94.53% 78.76% 219.59%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.06 0.06 0.05 0.24 0.25 0.61 0.88
Share Based Compensation of Revenue
39,209.76% 71,965.00% 2,497.65% (11,913.24%) 125.15% 31.47% 21.79% 7.48% 13.44% 29.83%
Graham Net Nets
0.70 0.24 0.34 0.23 0.49 0.73 1.24 5.70 (0.01) (247.02)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(27.98%) (18.59%) (15.68%) (11.32%) (25.76%) (16.93%) (80.42%) (844.58%) (178.27%) 2,962,960.00%
Free Cash Flow Yield
(21.30%) (15.64%) (13.58%) (8.58%) (23.95%) (11.98%) (38.82%) (179.98%) (78.62%) (93,802.49%)
Revenue per Share
0.00 0.00 0.01 0.00 0.11 0.32 0.44 3.69 24.86 14.06
Operating CF per Share
(0.77) (1.12) (1.42) (1.33) (1.90) (1.34) (0.73) (3.35) (46.80) (27.60)
Capex per Share
0.00 0.00 0.00 0.00 (0.30) (0.01) 0.00 (0.36) (0.37) (0.96)
Free Cash Flow per Share
(0.77) (1.12) (1.42) (1.34) (2.19) (1.35) (0.73) (3.71) (47.17) (28.56)
Cash per Share
3.10 1.86 3.72 3.94 4.61 8.42 2.84 12.26 28.49 12.49
Shareholders Equity per Share
2.55 1.74 3.65 3.95 4.82 8.81 3.47 17.24 91.22 139.91
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.55 1.74 3.65 3.95 4.82 8.81 3.47 17.24 91.22 139.91
Free Cash Flow
(67.55) (79.85) (75.86) (62.71) (90.55) (34.65) (9.63) (10.39) (20.37) (6.57)
Working Capital
263.20 126.79 197.48 175.76 185.85 218.24 35.47 34.84 19.63 (0.98)
Capital Expenditures
(0.01) — (0.05) (0.13) (12.31) (0.34) (0.03) (1.00) (0.16) (0.22)
Net Current Asset Value
223.16 121.46 193.09 171.18 184.40 211.02 30.86 32.93 (0.17) (1.71)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.53 0.65 0.00 0.24
Capex to Sales
0.27 0.00 0.11 (1.85) 2.79 0.04 0.01 0.10 0.01 0.07
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
(5.61) (8.75) 16.01 (0.19) 0.38 0.41 0.35 18.80 59.79 0.76
Cash ROIC
(12.68%) (31.26%) (19.35%) (16.91%) (23.18%) (7.82%) (11.43%) (12.49%) (39.41%) (18.73%)
Accounts Receivable Turnover
0.02 0.01 0.12 (0.02) 0.48 1.17 1.90 1.41 1.89 2.43
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 — — — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 — — — — —
Average Receivables
2.43 3.99 3.70 4.19 9.11 7.01 3.06 7.32 5.68 1.33
Average Payables
1.46 1.14 3.44 3.42 1.32 0.32 0.20 0.25 1.07 1.26
Average Assets
209.62 174.97 208.78 212.90 231.99 149.59 54.40 58.89 50.72 29.13
Average Common Equity
174.20 158.80 189.70 192.21 212.51 135.70 46.92 43.85 35.80 24.43

Fold the line items

Columns are period end dates